brexit-istock-537519806_andrewlinscott
andrewlinscott / iStockphoto.com
16 August 2019Big PharmaSaman Javed

Pharma bodies sign NDAs with UK govt over no-deal Brexit plans

Several pharma bodies have signed non-disclosure agreements (NDAs) which prevent them from disclosing the UK government’s plans for a no-deal Brexit.

In statements made to LSIPR yesterday, August 15, the Pharmaceutical Services Negotiating Committee ( PSNC), the British Generic Manufacturers Association ( BGMA) and the Association of the British Pharmaceutical Industry ( ABPI) confirmed that they had signed the NDAs.

In October 2018, the Department of Health and Social Care  asked the bodies to sign NDAs so the government could “talk to the industry in confidence” ahead of a possible no-deal Brexit.

In its request, the  government said it may need to take action to maintain the smooth supply of medicines to UK patients in the event of any disruption at the border.

It said that to be able to plan for this, it will need to share confidential and sensitive information about customs and border arrangements and supply routes.

Warwick Smith, the director general of the BGMA said the NDAs allowed the parties to assess the effectiveness of possible measures and to enable the government to agree the most effective plans.

But, he said as the departure date approaches, it was in the BGMA’s view “more important for the government to publish more detailed information on the planned mitigations as quickly as possible”.

Mike Thompson, the chief executive of ABPI, said it agreed to the NDA to support effective planning, but urged the government to secure a deal.

Thompson said: “Pharmaceutical companies have been doing everything in their power to prepare for Brexit.

“But some things remain outside of our control.  That’s why we continue to reiterate that securing a deal remains the best way to protect patients and public health.”

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
8 July 2019   The European Medicines Agency has ended a Brexit legal dispute over its Canary Wharf, London headquarters.
Big Pharma
21 August 2019   A leaked UK government report reveals that a no deal Brexit may result in shortages of medicines and other pharmaceutical products.
Big Pharma
3 September 2019   Leaving the EU without a deal in place could “irreparably” harm the UK’s National Health Service and lead to delays in new products being bought to market in the country, according to the British Medical Association.

More on this story

Europe
8 July 2019   The European Medicines Agency has ended a Brexit legal dispute over its Canary Wharf, London headquarters.
Big Pharma
21 August 2019   A leaked UK government report reveals that a no deal Brexit may result in shortages of medicines and other pharmaceutical products.
Big Pharma
3 September 2019   Leaving the EU without a deal in place could “irreparably” harm the UK’s National Health Service and lead to delays in new products being bought to market in the country, according to the British Medical Association.

More on this story

Europe
8 July 2019   The European Medicines Agency has ended a Brexit legal dispute over its Canary Wharf, London headquarters.
Big Pharma
21 August 2019   A leaked UK government report reveals that a no deal Brexit may result in shortages of medicines and other pharmaceutical products.
Big Pharma
3 September 2019   Leaving the EU without a deal in place could “irreparably” harm the UK’s National Health Service and lead to delays in new products being bought to market in the country, according to the British Medical Association.